Oncolytics Biotech Inc. (ONCY)
What's happening with ONCY?
Powered by Yahoo ScoutOncolytics Biotech is making significant strides with its investigational immunotherapy, pelareorep, particularly in colorectal cancer. Recent FDA feedback supports its pivotal trial pathway, while the company faces ongoing financial challenges and operational risks as it moves towards potential approvals.
- Previous Close
0.8565 - Open
0.8400 - Bid 0.5880 x 200
- Ask 1.1100 x 200
- Day's Range
0.8300 - 0.8522 - 52 Week Range
0.7300 - 1.5100 - Volume
463,255 - Avg. Volume
1,118,009 - Market Cap (intraday)
107.517M - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date (est.) Nov 16, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.25
Recent News
View MorePerformance Overview
Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
0.00%
-
Return on Assets (ttm)
-211.24%
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
-37.46M
-
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
-
Total Cash (mrq)
4.12M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-12.01M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
